Human Immunoglobulin E specific for Bet v 1 (Bet v 1-sIgE) (Bet v 1-sIgE)

Human Immunoglobulin E (IgE) specific for Bet v 1 is a key mediator of birch pollen allergy, which affects a significant portion of the population in temperate climates (Gould & Sutton, 2008, Nature). Bet v 1 is the major allergen of birch pollen, and the production of specific IgE antibodies against it leads to Type I hypersensitivity reactions (Neudecker et al., 2001, Journal of Biological Chemistry). These antibodies bind to high-affinity FcεRI receptors on the surface of mast cells and basophils; upon subsequent exposure to birch pollen, the allergen cross-links the IgE molecules, triggering the release of inflammatory mediators like histamine (NIH/NIAID). This process results in clinical symptoms such as allergic rhinitis, conjunctivitis, and asthma. Therapeutically, this target is addressed through monoclonal antibodies like omalizumab, which sequester free IgE, or through allergen-specific immunotherapy (AIT), which aims to desensitize the immune system and induce protective IgG4 antibodies (Valenta et al., 2019, Nature Reviews Immunology). Monitoring levels of Bet v 1-specific IgE is a standard diagnostic procedure for identifying birch pollen sensitization and assessing the risk of cross-reactive food allergies, known as oral allergy syndrome (StatPearls).

Other names

Anti-Bet v 1 IgEBirch pollen-specific IgEBet v 1-specific IgEAllergen-specific IgE to Bet v 1

Omalizumab binds to the Cε3 domain of the IgE molecule, preventing its interaction with the high-affinity FcεRI receptor on mast cells and basophils (Gould & Sutton, 2008, Nature). Allergen-specific immunotherapy (AIT) works by inducing the production of allergen-specific IgG4 antibodies that act as blocking antibodies, competing with IgE for allergen binding and thus preventing mast cell degranulation (Valenta et al., 2019, Nature Reviews Immunology).